{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:21:10Z","timestamp":1792552870765,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mmy\/myaf089","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T12:33:40Z","timestamp":1758976420000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"63","author":[{"given":"Ayano","family":"Kawasaki","sequence":"first","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuya","family":"Shintani","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Takao","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Mihara","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sora","family":"Shimada","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1936-910X","authenticated-orcid":false,"given":"Yuki","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Graduate School of Biomedical and Health Sciences, Hiroshima University , 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"issue":"6","key":"2025100905021109600_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/life13061335","article-title":"Changing trends in the incidence and clinical features of Pneumocystis jirovecii pneumonia in Non-HIV patients before and during the COVID-19 era and risk factors for mortality between 2016 and 2022","volume":"13","author":"Kang","year":"2023","journal-title":"Life"},{"issue":"8","key":"2025100905021109600_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan","volume":"63","author":"Hamada","year":"2020","journal-title":"Mycoses"},{"issue":"2","key":"2025100905021109600_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025100905021109600_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jiac.2018.04.014","article-title":"The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B","volume":"24","author":"Kato","year":"2018","journal-title":"J Infect Chemother"},{"issue":"SUPPL. 1","key":"2025100905021109600_bib5","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkm428","article-title":"New and emerging treatments for fungal infections","volume":"61","author":"Pasqualotto","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2025100905021109600_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mycmed.2018.02.002","article-title":"Isavuconazole: A new broad-spectrum azole. Part 2: Pharmacokinetics and clinical activity","volume":"28","author":"Ledoux","year":"2018","journal-title":"J Mycol Med"},{"issue":"1","key":"2025100905021109600_bib7","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1038\/s41467-018-05497-7","article-title":"Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus","volume":"9","author":"Gei\u00dfel","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2025100905021109600_bib8","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jac\/dkl396","article-title":"Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus","volume":"58","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2025100905021109600_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2025100905021109600_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"2025100905021109600_bib11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/03007995.2018.1502659","article-title":"Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis","volume":"34","author":"Herbrecht","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"2025100905021109600_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/myc.13622","article-title":"A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections","volume":"66","author":"Kato","year":"2023","journal-title":"Mycoses"},{"issue":"1","key":"2025100905021109600_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12879-025-10627-w","article-title":"Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: A meta-analysis with trial sequential analysis","volume":"25","author":"Weng","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2025100905021109600_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jiac.2022.10.010","article-title":"Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan","volume":"29","author":"Kohno","year":"2023","journal-title":"J Infect Chemother"},{"issue":"11","key":"2025100905021109600_bib15","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/myc.12831","article-title":"Treatment outcomes in patients with proven\/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole","volume":"61","author":"Maertens","year":"2018","journal-title":"Mycoses"},{"issue":"12","key":"2025100905021109600_bib16","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2025100905021109600_bib17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/cpdd.1079","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of isavuconazonium sulfate in healthy adult Japanese subjects","volume":"11","author":"Shirae","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"2025100905021109600_bib18","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"10020","key":"2025100905021109600_bib19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"The Lancet"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myaf089\/64418155\/myaf089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/63\/10\/myaf089\/64418155\/myaf089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/63\/10\/myaf089\/64418155\/myaf089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:05:26Z","timestamp":1760000726000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myaf089\/8266816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myaf089","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,27]]},"article-number":"myaf089"}}